Adams Sharon, Robbins Fu-Meei, Chen Deborah, Wagage Devika, Holbeck Susan L, Morse Herbert C, Stroncek David, Marincola Francesco M
Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, 20892, USA.
J Transl Med. 2005 Mar 4;3(1):11. doi: 10.1186/1479-5876-3-11.
Sixty cancer cell lines have been extensively characterized and used by the National Cancer Institute's Developmental Therapeutics Program (NCI-60) since the early 90's as screening tools for anti-cancer drug development. An extensive database has been accumulated that could be used to select individual cells lines for specific experimental designs based on their global genetic and biological profile. However, information on the human leukocyte antigen (HLA) genotype of these cell lines is scant and mostly antiquated since it was derived from serological typing. We, therefore, re-typed the NCI-60 panel of cell lines by high-resolution sequence-based typing. This information may be used to: 1) identify and verify the identity of the same cell lines at various institutions; 2) check for possible contaminant cell lines in culture; 3) adopt individual cell lines for experiments in which knowledge of HLA molecule expression is relevant. Since genome-based typing does not guarantee actual surface protein expression, further characterization of relevant cell lines should be entertained to verify surface expression in experiments requiring correct antigen presentation.
自20世纪90年代初以来，美国国立癌症研究所的发展治疗项目（NCI-60）对60种癌细胞系进行了广泛的特征分析，并将其用作抗癌药物开发的筛选工具。已经积累了一个广泛的数据库，可用于根据其整体遗传和生物学特征为特定实验设计选择单个细胞系。然而，这些细胞系的人类白细胞抗原（HLA）基因型信息很少，而且大多过时，因为它来自血清学分型。因此，我们通过基于序列的高分辨率分型对NCI-60细胞系进行了重新分型。这些信息可用于：1）识别和验证不同机构中同一细胞系的身份；2）检查培养物中可能存在的污染细胞系；3）在与HLA分子表达知识相关的实验中采用单个细胞系。由于基于基因组的分型不能保证实际的表面蛋白表达，在需要正确抗原呈递的实验中，应考虑对相关细胞系进行进一步表征以验证表面表达。
